Tau Progression ANd THERapeutics (TAU-PANTHER) study
Research type
Research Study
Full title
Tau Progression ANd THERapeutics (TAU-PANTHER) study
IRAS ID
299165
Contact name
Edwin Jabbari
Contact email
Sponsor organisation
UCLH/UCL Joint Research Office, part of the Research Directorate
Clinicaltrials.gov Identifier
Z6364106/2022/11/31, Data Protection Reference Number
Duration of Study in the UK
4 years, 0 months, 1 days
Research summary
Tau-related disorders are neurodegenerative conditions that are characterised by the accumulation of pathological tau pathology in the brain. Examples include Progressive Supranuclear Palsy (PSP), Corticobasal syndrome (CBS) and Alzheimer's disease (AD). We need to develop effective disease modifying therapies for these conditions and we believe that this can be done through an integrated study of genetics, the change in levels of certain proteins found in blood and spinal fluid over time, and how these relate to the clinical and cognitive changes in patients over time.
Being involved in the study will involve: a) reading the project information sheet and completing a consent form; b) attending a research assessment on 2 occasions over 2 years; c) having a neurological assessment which will take 45 minutes; d) completing questionnaires; e) donating blood, urine and spinal fluid samples for research; f) agreeing that you can be contacted by phone or at a clinic appointment on two more occasions at 3 and 5 years. Initially, the study will focus on patients who have been diagnosed with PSP but with time, the study will evolve to also include patients diagnosed with CBS and AD. People unaffected by neurological disease will be asked to participate in the study on one occasion by completing all of the above apart from the neurological assessment.
We hope that the findings from this study will help to discover and assess the potential of new treatment targets for tau-related diseases.
REC name
London - Camden & Kings Cross Research Ethics Committee
REC reference
23/LO/0160
Date of REC Opinion
26 Apr 2023
REC opinion
Further Information Favourable Opinion